Related Experiment Video

Updated: May 16, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections

Doina Azoicai1, Sabina Antonela Antoniu

  • 1University of Medicine and Pharmacy Grigore T Popa Iasi, Interdisciplinarity, Str. Universităţii nr 16, Iasi, 700115, Romania.

Expert Opinion on Investigational Drugs
|November 27, 2012
PubMed
Abstract

Insights

Inhaled antibiotics like MP-376 offer a promising treatment for chronic Pseudomonas aeruginosa (PA) lung infections, overcoming challenges of resistance and poor systemic drug delivery in conditions like cystic fibrosis.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Chronic Pseudomonas aeruginosa (PA) infection is a key factor in the progression of chronic lung diseases such as cystic fibrosis and COPD.
  • PA infections present significant therapeutic challenges due to host defense mechanisms and rapid antibiotic resistance.
  • Systemic antibiotics often fail to achieve adequate drug concentrations in the lungs.

Purpose of the Study:

  • To review preclinical and clinical data on MP-376 for treating chronic airway infections caused by PA.
  • To evaluate the efficacy and safety profile of MP-376 in managing PA lung infections.

Main Methods:

  • Comprehensive review of existing preclinical studies.
  • Analysis of available clinical trial data for MP-376.
  • Focus on efficacy and safety data related to PA infections.

Main Results:

  • MP-376 is in late-stage clinical development for treating chronic airway infections.
  • Inhaled antibiotics demonstrate superior lung penetration and lower systemic exposure compared to systemic counterparts.
  • MP-376 shows potential as an effective inhaled therapy against PA.

Conclusions:

  • Chronic PA airway infections are difficult to treat, necessitating novel therapeutic strategies.
  • Inhaled antibiotics, including MP-376, are advantageous due to improved lung delivery and reduced systemic side effects.
  • Inhaled levofloxacin is also under investigation as a potential antipseudomonal inhaled therapy.

More Related Videos

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...